Status:
UNKNOWN
Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA
Lead Sponsor:
CHU de Reims
Conditions:
Chronic Hemolysis
VKA
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Use HeprAN ™ membrane (coated with heparin) should be allow the success of dialysis sessions, with adequate dialysis parameters, in patients treated by long-term anticoagulation with VKA, without addi...
Detailed Description
The aim will be to study possibility of hemodialysis sessions success, without perdialytic anticoagulation but with adequate dialysis parameters (defined by the patient's Kt / V machine), in patients ...
Eligibility Criteria
Inclusion
- inclusion criteria :
- 18 years old and older
- chronic hemodialysis for at least 3 months
- treated by long-term anticoagulation with VKA
- hemodialysis with the HeprAN® membrane
- per dialytic heparin therapy (UFH or LMWH)
- dialyzed at Reims University Hospital
- agreeing to participate in the study
- Exclusion criteria
- chronic hemodialysis without per dialytic heparin
- Patient dialized with single lumen catheter for vascular access
- less than 18 years old
- pregnant or lactating women
- protected by law
Exclusion
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2021
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04462614
Start Date
August 1 2020
End Date
July 1 2021
Last Update
July 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien JOLLY
Reims, France